Prognosis

Eli Lilly’s Virus Antibody Drug Starts Testing in Nursing Homes

  • Antibody could work as alternative to vaccine for older people
  • Co. to make 100,000 doses by year’s end if trial succeeds
Photographer: Daniel Acker/Bloomberg
Lock
This article is for subscribers only.

Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.

Eli Lilly & Co. will begin testing its Covid-19 antibody drug in nursing homes, a treatment with potential to protect vulnerable groups that vaccines may not cover.